TRANSFORM-HF Mortality Comparison Index

Clinical calculation support · Verify results before clinical use

Randomized trial outcome

Published results comparing torsemide with furosemide after hospitalization for heart failure.

Evidence summary · RCT

TRANSFORM-HF randomized 2,859 patients hospitalized with heart failure, regardless of ejection fraction, to a torsemide or furosemide treatment strategy. The figures below are observed trial-group outcomes, not individualized predictions.

Torsemide group
26.1%
All-cause mortality: 373 of 1,431 participants.
Furosemide group
26.2%
All-cause mortality: 374 of 1,428 participants.
Primary outcome: HR 1.02 (95% CI 0.89–1.18; P = .76). The trial did not demonstrate a statistically significant difference in all-cause mortality between the treatment strategies.

Selected 12-month outcomes

OutcomeTorsemideFurosemideEffect estimate
All-cause mortality26.1%26.2%HR 1.02 (95% CI 0.89–1.18)
Death or all-cause hospitalization47.3%49.3%HR 0.92 (95% CI 0.83–1.02)
Total hospitalizations940987Rate ratio 0.94 (95% CI 0.84–1.07)

Clinical interpretation

TRANSFORM-HF compared post-discharge loop-diuretic strategies in a pragmatic, open-label randomized trial. Its primary mortality result was neutral; the confidence interval includes both possible benefit and possible harm.

What these results mean

  • The observed mortality proportions were very similar between randomized groups.
  • The primary outcome did not establish a mortality advantage for torsemide over furosemide.
  • Secondary estimates also had confidence intervals that included no difference.
  • Diuretic selection should be individualized to clinical response, congestion, renal function, dose, adherence, availability, and clinician judgement—not to an unvalidated mortality estimate.

Important limitation

The supplied original code included a logistic equation with coefficients described as an approximation, plus a modeled 5% torsemide adjustment. The source code did not provide a validated derivation, calibration, discrimination, or external validation for that equation. Those calculations have therefore not been retained as patient-level risk estimates.

Primary reference

Mentz RJ, Anstrom KJ, Eisenstein EL, et al. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA. 2023;329(3):214–223. doi:10.1001/jama.2022.23924. PMID: 36648467. Read the PubMed record Read the full article at JAMA Network
Trial registration: TRANSFORM-HF ClinicalTrials.gov identifier: NCT03296813. View trial registration